Acute mountain sickness impact among travelers to cusco, peru

Hugo Salazar, Jessica Swanson, Karen Mozo, A. Clinton White, Miguel Cabada

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background Increasing numbers of travelers are visiting high altitude locations in the Andes. The epidemiology of acute mountain sickness (AMS) among tourists to high altitude in South America is not well understood. Methods A cross-sectional study to evaluate the epidemiology, pre-travel preparation, and impact of AMS among travelers to Cusco, Peru (3,400 m) was performed at Cusco's International Airport during June 2010. Foreign travelers, 18 years or older, staying 15 days or less, departing Cusco were invited to participate. Demographic, itinerary, and behavioral data were collected. The Lake Louise Clinical score (LLCS) was used to assess AMS symptoms. Results In total, 991 travelers participated, median age 32 years (interquartile range 25-49), 55.5% female, 86.7% tourists, mostly from the United States (48.2%) and England (8.1%). Most (76.7%) flew from sea level to Cusco and 30.5% visited high altitude in the previous 2 months. Only 29.1% received AMS advice from a physician, 19% recalled advice on acetazolamide. Coca leaf products (62.8%) were used more often than acetazolamide (16.6%) for prevention. AMS was reported by 48.5% and 17.1% had severe AMS. One in five travelers with AMS altered their travel plans. Travelers older than 60 years, with recent high altitude exposure, who visited lower cities in their itinerary, or used acetazolamide were less likely to have AMS. Using coca leaf products was associated with increased AMS frequency. Conclusions AMS was common and adversely impacted plans of one in five travelers. Acetazolamide was associated with decreased AMS but was prescribed infrequently. Other preventive measures were not associated with a decrease in AMS in this population. Pre-travel preparation was suboptimal.

Original languageEnglish (US)
Pages (from-to)220-225
Number of pages6
JournalJournal of Travel Medicine
Volume19
Issue number4
DOIs
StatePublished - Jul 2012

Fingerprint

Altitude Sickness
Peru
Acetazolamide
Epidemiology
Airports
South America
Lakes
Oceans and Seas
England

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Acute mountain sickness impact among travelers to cusco, peru. / Salazar, Hugo; Swanson, Jessica; Mozo, Karen; White, A. Clinton; Cabada, Miguel.

In: Journal of Travel Medicine, Vol. 19, No. 4, 07.2012, p. 220-225.

Research output: Contribution to journalArticle

Salazar, Hugo ; Swanson, Jessica ; Mozo, Karen ; White, A. Clinton ; Cabada, Miguel. / Acute mountain sickness impact among travelers to cusco, peru. In: Journal of Travel Medicine. 2012 ; Vol. 19, No. 4. pp. 220-225.
@article{12b77e43f75a41338df5fb30ff665fad,
title = "Acute mountain sickness impact among travelers to cusco, peru",
abstract = "Background Increasing numbers of travelers are visiting high altitude locations in the Andes. The epidemiology of acute mountain sickness (AMS) among tourists to high altitude in South America is not well understood. Methods A cross-sectional study to evaluate the epidemiology, pre-travel preparation, and impact of AMS among travelers to Cusco, Peru (3,400 m) was performed at Cusco's International Airport during June 2010. Foreign travelers, 18 years or older, staying 15 days or less, departing Cusco were invited to participate. Demographic, itinerary, and behavioral data were collected. The Lake Louise Clinical score (LLCS) was used to assess AMS symptoms. Results In total, 991 travelers participated, median age 32 years (interquartile range 25-49), 55.5{\%} female, 86.7{\%} tourists, mostly from the United States (48.2{\%}) and England (8.1{\%}). Most (76.7{\%}) flew from sea level to Cusco and 30.5{\%} visited high altitude in the previous 2 months. Only 29.1{\%} received AMS advice from a physician, 19{\%} recalled advice on acetazolamide. Coca leaf products (62.8{\%}) were used more often than acetazolamide (16.6{\%}) for prevention. AMS was reported by 48.5{\%} and 17.1{\%} had severe AMS. One in five travelers with AMS altered their travel plans. Travelers older than 60 years, with recent high altitude exposure, who visited lower cities in their itinerary, or used acetazolamide were less likely to have AMS. Using coca leaf products was associated with increased AMS frequency. Conclusions AMS was common and adversely impacted plans of one in five travelers. Acetazolamide was associated with decreased AMS but was prescribed infrequently. Other preventive measures were not associated with a decrease in AMS in this population. Pre-travel preparation was suboptimal.",
author = "Hugo Salazar and Jessica Swanson and Karen Mozo and White, {A. Clinton} and Miguel Cabada",
year = "2012",
month = "7",
doi = "10.1111/j.1708-8305.2012.00606.x",
language = "English (US)",
volume = "19",
pages = "220--225",
journal = "Journal of Travel Medicine",
issn = "1195-1982",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Acute mountain sickness impact among travelers to cusco, peru

AU - Salazar, Hugo

AU - Swanson, Jessica

AU - Mozo, Karen

AU - White, A. Clinton

AU - Cabada, Miguel

PY - 2012/7

Y1 - 2012/7

N2 - Background Increasing numbers of travelers are visiting high altitude locations in the Andes. The epidemiology of acute mountain sickness (AMS) among tourists to high altitude in South America is not well understood. Methods A cross-sectional study to evaluate the epidemiology, pre-travel preparation, and impact of AMS among travelers to Cusco, Peru (3,400 m) was performed at Cusco's International Airport during June 2010. Foreign travelers, 18 years or older, staying 15 days or less, departing Cusco were invited to participate. Demographic, itinerary, and behavioral data were collected. The Lake Louise Clinical score (LLCS) was used to assess AMS symptoms. Results In total, 991 travelers participated, median age 32 years (interquartile range 25-49), 55.5% female, 86.7% tourists, mostly from the United States (48.2%) and England (8.1%). Most (76.7%) flew from sea level to Cusco and 30.5% visited high altitude in the previous 2 months. Only 29.1% received AMS advice from a physician, 19% recalled advice on acetazolamide. Coca leaf products (62.8%) were used more often than acetazolamide (16.6%) for prevention. AMS was reported by 48.5% and 17.1% had severe AMS. One in five travelers with AMS altered their travel plans. Travelers older than 60 years, with recent high altitude exposure, who visited lower cities in their itinerary, or used acetazolamide were less likely to have AMS. Using coca leaf products was associated with increased AMS frequency. Conclusions AMS was common and adversely impacted plans of one in five travelers. Acetazolamide was associated with decreased AMS but was prescribed infrequently. Other preventive measures were not associated with a decrease in AMS in this population. Pre-travel preparation was suboptimal.

AB - Background Increasing numbers of travelers are visiting high altitude locations in the Andes. The epidemiology of acute mountain sickness (AMS) among tourists to high altitude in South America is not well understood. Methods A cross-sectional study to evaluate the epidemiology, pre-travel preparation, and impact of AMS among travelers to Cusco, Peru (3,400 m) was performed at Cusco's International Airport during June 2010. Foreign travelers, 18 years or older, staying 15 days or less, departing Cusco were invited to participate. Demographic, itinerary, and behavioral data were collected. The Lake Louise Clinical score (LLCS) was used to assess AMS symptoms. Results In total, 991 travelers participated, median age 32 years (interquartile range 25-49), 55.5% female, 86.7% tourists, mostly from the United States (48.2%) and England (8.1%). Most (76.7%) flew from sea level to Cusco and 30.5% visited high altitude in the previous 2 months. Only 29.1% received AMS advice from a physician, 19% recalled advice on acetazolamide. Coca leaf products (62.8%) were used more often than acetazolamide (16.6%) for prevention. AMS was reported by 48.5% and 17.1% had severe AMS. One in five travelers with AMS altered their travel plans. Travelers older than 60 years, with recent high altitude exposure, who visited lower cities in their itinerary, or used acetazolamide were less likely to have AMS. Using coca leaf products was associated with increased AMS frequency. Conclusions AMS was common and adversely impacted plans of one in five travelers. Acetazolamide was associated with decreased AMS but was prescribed infrequently. Other preventive measures were not associated with a decrease in AMS in this population. Pre-travel preparation was suboptimal.

UR - http://www.scopus.com/inward/record.url?scp=84863719681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863719681&partnerID=8YFLogxK

U2 - 10.1111/j.1708-8305.2012.00606.x

DO - 10.1111/j.1708-8305.2012.00606.x

M3 - Article

C2 - 22776382

AN - SCOPUS:84863719681

VL - 19

SP - 220

EP - 225

JO - Journal of Travel Medicine

JF - Journal of Travel Medicine

SN - 1195-1982

IS - 4

ER -